<!DOCTYPE html>
<html>


<head>
    <!-- standard head -->
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <script type="text/javascript"
        src="https://2019.igem.org/wiki/index.php?title=Team:SYSU-Medicine/js/jquery&action=raw&ctype=text/javascript"></script>
    <link type="text/css" rel="stylesheet"
        href="https://2019.igem.org/wiki/index.php?title=Team:SYSU-Medicine/css/default&action=raw&ctype=text/css" />
    <script type="text/javascript"
        src="https://2019.igem.org/wiki/index.php?title=Team:SYSU-Medicine/js/navigation&action=raw&ctype=text/javascript"></script>
    <link rel="stylesheet"
        href="https://2019.igem.org/wiki/index.php?title=Team:SYSU-Medicine/css/bootstrap&action=raw&ctype=text/css">
    <script
        src="https://2019.igem.org/wiki/index.php?title=Team:SYSU-Medicine/js/bootstrap&action=raw&ctype=text/javascript"></script>
    <link type="text/css" rel="stylesheet"
        href="https://2019.igem.org/wiki/index.php?title=Team:SYSU-Medicine/css/navigation&action=raw&ctype=text/css" />
    <!-- standard head end -->

    <link type="text/css" rel="stylesheet" href="./Description.css">


    <script src="./Description.js"></script>

    <title>Description</title>

</head>

<body>
    <!-- <div class="debug" style= "position:fixed;top:6rem">
        <a class="a">a</a>
    </div> -->
    <div class="container">
            <div class="row">
                <div class="col-sm-12 column">
                    <nav class="navigation" id="nav-top">
                        <ul class="navigation-list nav-justified">
                            <div class="navigation-blue navigation-div">
                                <li class="navigation-item activate ">
                                    <a class="navigation-item-link "
                                        href="https://2019.igem.org/Team:SYSU-Medicine">Home</a>
                                    <ul class="navigation-dropdown-panel"></ul>
                                </li>
    
                                <li class="navigation-item dropdown">
                                    <a class="navigation-item-link " href="#">Project</a>
                                    <ul class="navigation-dropdown-panel ">
    
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Inspiration">Inspiration</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Description">Description</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Results">Results</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Contribution">Contribution</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Notebook">Notebook</a>
                                        </li>
                                    </ul>
                                </li>
                                <li class="navigation-item dropdown">
                                    <a class="navigation-item-link"
                                        href="https://2019.igem.org/Team:SYSU-Medicine/Model">Model</a>
                                    <ul class="navigation-dropdown-panel">
                                            <li class="navigation-subitem">
                                                    <a href="https://2019.igem.org/Team:SYSU-Medicine/Model">Overview</a>
                                                </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/M1_Cultivation">M1
                                                Cultivation</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Injection_System">Injection
                                                System</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Safety_and_Effectiveness">Safety
                                                and Effectiveness</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Future">Future</a>
                                        </li>
                                    </ul>
                                </li>
                                <li class="navigation-item dropdown ">
                                    <a class="navigation-item-link" href="#">Human Practices</a>
                                    <ul class="navigation-dropdown-panel ">
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Human_Practices">Human
                                                Practices</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Public_Engagement">Education &
                                                Engagement</a>
                                        </li>
                                    </ul>
                                </li>
    
                            </div>
                            <div class="navigation-red navigation-div">
                                <li class="navigation-item dropdown ">
                                    <a class="navigation-item-link " href="#">Parts</a>
                                    <ul class="navigation-dropdown-panel ">
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Parts">Parts Overview</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Basic_Part">Basic Parts</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Composite_Part">Composite
                                                Parts</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Part_Collection">Part
                                                Collection</a>
                                        </li>
                                    </ul>
                                </li>
                                <li class="navigation-item dropdown ">
                                    <a class="navigation-item-link " href="#">Team</a>
                                    <ul class="navigation-dropdown-panel ">
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Team">Team Members</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a
                                                href="https://2019.igem.org/Team:SYSU-Medicine/Collaborations">Collaborations</a>
                                        </li>
                                        <li class="navigation-subitem">
                                            <a href="https://2019.igem.org/Team:SYSU-Medicine/Attributions">Attributions</a>
                                        </li>
                                    </ul>
                                </li>
                                <li class="navigation-item ">
                                    <a class="navigation-item-link"
                                        href="https://2019.igem.org/Team:SYSU-Medicine/Safety">Safety</a>
                                    <ul class="navigation-dropdown-panel"></ul>
                                </li>
                                <li class="navigation-item ">
                                    <a class="navigation-item-link"
                                        href="https://igem.org/2019_Judging_Form?team=SYSU-Medicine">Judging Form</a>
                                    <ul class="navigation-dropdown-panel"></ul>
                                </li>
                            </div>
    
                        </ul>
                    </nav>
                </div>
            </div>
        </div>


    <!-- <div class="piano-subpage piano-subpage-demo">
    <div id="content-0-key" class="piano-subpage-key piano-subpage-key-0"><div class="key-kernel key-kernel-0"></div></div>
    <div id="content-1-key" class="piano-subpage-key piano-subpage-key-1"><div class="key-kernel key-kernel-1"></div></div>
    <div id="content-2-key" class="piano-subpage-key piano-subpage-key-2"><div class="key-kernel key-kernel-2"></div></div>
    <div id="content-3-key" class="piano-subpage-key piano-subpage-key-3"><div class="key-kernel key-kernel-3"></div></div>
    <div id="content-4-key" class="piano-subpage-key piano-subpage-key-4"><div class="key-kernel key-kernel-4"></div></div>
    <div id="content-5-key" class="piano-subpage-key piano-subpage-key-5"><div class="key-kernel key-kernel-5"></div></div>
    </div> -->
    <!-- <div class="title-margin">
        <div class="row clearfix">
            <div class="col-xs-10">
                <div class="title-box">
                    <h1 class="title">
                        <span class="title-has-mask playing">Human Practices</span>
                        <span class="title-mask playing"></span>
                    </h1>
                </div>
            </div>
        </div>
    </div> -->
    <div class="title-box-new title-big">
        <div class="title-box-mask"></div>
        <div class="title-box-title">
            <h1>DESCRIPTION</h1>
        </div>
    </div>
    <div class="title-box-new title-0">
        <div class="title-box-mask"></div>
        <div class="title-box-title">
            <h1>BACK GROUND</h1>
        </div>
    </div>
    <div class="introduction">
        <p>
            “Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million
            deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.”</p>
        <p> &nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp——WHO
        </p>

    </div>
    <div class="sub-content need-scale need-scale-0" id="content-0">
        <div class="switch"></div>
        <div class="mask-front-content-box">
            <div class="mask-front-content mask-front-content-00">
                <p>Cancer and Therapies
                </p>
            </div>
            <div class="mask-front-content mask-front-content-01">
                <p>
                    M1

                </p>
            </div>
        </div>

        <div class="mask mask-0-box">
            <div class="mask-0 m00">

            </div>
            <div class="mask-0 m01">

            </div>
        </div>
        <div class="content-0-all">
           <div class=" rich-content-box-shadow">
            <div class=" rich-content-00">
                <img src="https://2019.igem.org/wiki/images/thumb/d/d7/T--SYSU-Medicine--background_1.png/1600px-T--SYSU-Medicine--background_1.png"
                    class="img-bg-1">
                <p>&nbsp&nbsp&nbsp&nbspNeedless to say, there are tons of data on the importance and dangers of cancer,
                    but it was only when
                    we came to the hospital to practice that we really realized how prevailing and frightening this
                    disease is. We have witnessed with our own eyes the suffering of our patients, the incessant
                    coughing of patients with lung cancer, the excruciating appearance of patients with stomach cancer,
                    and the huge abdomen filled with ascites of patients with liver cancer.
                </p>
                <p><b>
                        &nbsp&nbsp&nbsp&nbspAll this moved us deeply, and led us to think deeply ——how can we actually
                        relieve their pain? What efforts can we make as a group of medical students?</b>
                </p>
                
            </div>
            <div class=" rich-content-01 ">
                <img src="https://2019.igem.org/wiki/images/thumb/4/4a/T--SYSU-Medicine--background_2.png/1600px-T--SYSU-Medicine--background_2.png"
                    class="img-bg-0">
                <p>&nbsp&nbsp&nbsp&nbspM1 is a strain of Getah-like alphavirus that was isolated from culicine
                    mosquitoes collected on
                    Hainan Island of China which possesses selective and potent antitumor activity through
                    intravenous
                    infusion [2].</p>
                <p>

                    &nbsp&nbsp&nbsp&nbspCompared with other oncolytic virus, the most significant advantage of M1 is
                    that it is highly safe
                    and can be injected intravenously. Getah virus is transmitted mainly among horses and pigs, and
                    it
                    has not been linked to human illness [3]. 
                </p>
                <p>
                    &nbsp&nbsp&nbsp&nbsp At the same time, studies have shown that M1 has a broad anti-cancer
                    
                </p>
            </div>
        </div>

        <div class="rich-content-box ">
            <div class=" rich-content-00 need-scale need-scale-rich-0">
                <img src="https://2019.igem.org/wiki/images/thumb/d/d7/T--SYSU-Medicine--background_1.png/1600px-T--SYSU-Medicine--background_1.png"
                    class="img-bg-1">
                <p>&nbsp&nbsp&nbsp&nbspNeedless to say, there are tons of data on the importance and dangers of
                    cancer,
                    but it was only when
                    we came to the hospital to practice that we really realized how prevailing and frightening this
                    disease is. We have witnessed with our own eyes the suffering of our patients, the incessant
                    coughing of patients with lung cancer, the excruciating appearance of patients with stomach
                    cancer,
                    and the huge abdomen filled with ascites of patients with liver cancer.
                </p>
                <p><b>
                        &nbsp&nbsp&nbsp&nbspAll this moved us deeply, and led us to think deeply ——how can we
                        actually
                        relieve their pain? What efforts can we make as a group of medical students?</b>
                </p>
                <p>
                    &nbsp&nbsp&nbsp&nbspNowadays, targeted and immune-based therapies have already transformed the
                    standard-of‑care for
                    several malignancies. Oncolytic virus, as an attractive therapeutic combination of
                    tumor-specific
                    cell lysis together with immune stimulation, are emerging as important agents in cancer
                    treatment.
                </p>
                <p>
                    &nbsp&nbsp&nbsp&nbspOncolytic virus (OV) immunotherapy is a therapeutic approach to cancer
                    treatment
                    that utilizes
                    native or genetically modified viruses that selectively replicate within tumor cells. OVs
                    mediate
                    antitumor activity through two distinct mechanisms of action: selective replication within
                    neoplastic cells, resulting in a direct lytic effect on tumor cells; and induction of systemic
                    antitumor immunity [1].

                </p>
            </div>
            <div class=" rich-content-01 need-scale need-scale-rich-0">
                <img src="https://2019.igem.org/wiki/images/thumb/4/4a/T--SYSU-Medicine--background_2.png/1600px-T--SYSU-Medicine--background_2.png"
                    class="img-bg-0">
                <p>&nbsp&nbsp&nbsp&nbspM1 is a strain of Getah-like alphavirus that was isolated from culicine
                    mosquitoes collected on
                    Hainan Island of China which possesses selective and potent antitumor activity through
                    intravenous
                    infusion [2].</p>
                <p>

                    &nbsp&nbsp&nbsp&nbspCompared with other oncolytic virus, the most significant advantage of M1 is
                    that it is highly safe
                    and can be injected intravenously. Getah virus is transmitted mainly among horses and pigs, and
                    it
                    has not been linked to human illness [3]. 
                </p>
                <p>
                    &nbsp&nbsp&nbsp&nbspAt the same time, studies have shown that M1 has a broad anti-cancer
                    spectrum.
                    It can selectively
                    infect and kill 13 kinds of refractory high-incidence malignant tumor cells through triple
                    mechanism
                    of direct oncolytic, peripheral cell killing and immune activation, but has no killing effect on
                    normal cells.
                </p>
                <p>
                    &nbsp&nbsp&nbsp&nbspTo sum up, oncolytic virus M1 has the advantages of broad anti-tumor
                    spectrum,
                    safety,
                    effectiveness, precision treatment, etc. It has a good potential for cancer treatment and could
                    serve as a good foundation and platform for further synthetic biology research.

                </p>
            </div>
        </div> 
        </div>
        



    </div>
    <div class="title-box-new title-1">
        <div class="title-box-mask"></div>
        <div class="title-box-title">
            <h1>Problem Definition</h1>
        </div>
    </div>
    <div class="sub-content" id="content-1">
        <div class="switch"></div>
        <div class="mask-front-content-box ">
            <div class="mask-front-content mask-front-content-10">
                <p>【Shortages of Current Cancer Therapies】


                </p>
            </div>
            <div class="mask-front-content mask-front-content-11">
                <p>
                    【Side Effects of Actinomycin D】

                </p>
            </div>
            <div class="mask-front-content mask-front-content-12">
                <p>
                    【Low Sensitivity of M1】

                </p>
            </div>
            <div class="mask-front-content mask-front-content-13">
                <p>
                    【Effective Regulation】

                </p>
            </div>
        </div>
        <div class="mask mask-1-box">

            <div class="content-1s">
                <div class="mask-1 m10"></div>
                <div class="mask-1 m11"></div>


            </div>
            <div class="content-1s">
                <div class="mask-1 m12"></div>
                <div class="mask-1 m13"></div>
            </div>
        </div>
        <div class="rich-content-box rich-content-box-1">
            <div class="rich-content rich-content-10">
                <img src="https://2019.igem.org/wiki/images/thumb/2/2a/T--SYSU-Medicine--problem_definition_1.png/1600px-T--SYSU-Medicine--problem_definition_1.png"
                    class="img-pd-0">
                <p>
                    &nbsp&nbsp&nbsp&nbspCurrent cancer treatments are either limited in their effectiveness or have
                    large side effects.
                </p>
            </div>
            <div class="rich-content rich-content-11">
                <img src="https://2019.igem.org/wiki/images/thumb/7/7e/T--SYSU-Medicine--problem_definition_2.png/1600px-T--SYSU-Medicine--problem_definition_2.png"
                    class="img-pd-1">
                <p>
                    &nbsp&nbsp&nbsp&nbspSevere side effects in the bone marrow, lymphoid tissues, and intestinal
                    epithelium [4].
                </p>
            </div>
            <div class="rich-content rich-content-12">
                <img src="https://2019.igem.org/wiki/images/thumb/b/b8/T--SYSU-Medicine--problem_definition_3.png/1600px-T--SYSU-Medicine--problem_definition_3.png"
                    class="img-pd-2">
                <p>
                    &nbsp&nbsp&nbsp&nbspOncolytic virus M1 may be a viable solution for its high targeting ability
                    and
                    broad anticancer
                    spectrum, it does not have a significant oncolytic effect on all subtypes of tumor cells.
                </p>
            </div>
            <div class="rich-content rich-content-13">
                <img src="https://2019.igem.org/wiki/images/thumb/d/d9/T--SYSU-Medicine--approach_2.png/1600px-T--SYSU-Medicine--approach_2.png"
                    class="img-pd-3">
                <p>
                    &nbsp&nbsp&nbsp&nbspWe still lack operable regulation of it, such as the cessation of M1 virus
                    infection after effective
                    clearance of tumor cells.
                </p>
            </div>
        </div>


    </div>
    <div class="title-box-new title-2">
        <div class="title-box-mask"></div>
        <div class="title-box-title">
            <h1>Approach</h1>
        </div>
    </div>
    <div class="sub-content" id="content-2">
        <div class="switch"></div>
        <div class="mask-front-content-box">
            <div class="mask-front-content mask-front-content-20">
                <p>Enzyme Prodrug System
                </p>
            </div>
            <div class="mask-front-content mask-front-content-21">
                <p>
                    Riboswitch

                </p>
            </div>
        </div>
        <div class="mask mask-2-box">
            <div class="mask-2 m20"></div>
            <div class="mask-2 m21"></div>
        </div>
        <div class="rich-content-box">
            <div class="rich-content rich-content-20">
                <img src="https://2019.igem.org/wiki/images/thumb/6/60/T--SYSU-Medicine--approach_1.png/1600px-T--SYSU-Medicine--approach_1.png"
                    class="img-approach-0">
                <p>
                    Our project is to engineer M1 to specifically encode and express enzymes that can convert
                    prodrugs
                    into active therapeutic metabolites, and enhance bystander effects.
                </p>
            </div>
            <div class="rich-content rich-content-21">
                <img src="https://2019.igem.org/wiki/images/thumb/d/d9/T--SYSU-Medicine--approach_2.png/1600px-T--SYSU-Medicine--approach_2.png"
                    class="img-approach-1">
                <p>
                    We also utilize riboswitch to enhance the dynamic regulation of M1. It comprises a ribozyme
                    actuator
                    and RNA aptamer sensor and is engineered into the replicon 3’UTR.
                </p>
            </div>
        </div>



    </div>
    <div class="title-box-new title-3">
        <div class="title-box-mask"></div>
        <div class="title-box-title">
            <h1>Future Perspectives</h1>
        </div>
    </div>
    <div class="sub-content" id="content-3">
        <div class="switch"></div>
        <div class="mask-front-content-box">
            <!-- <div class="mask-front-content mask-front-content-30">
                <p>Building better oncolytic virus
                </p>
            </div> -->
            <div class="mask-front-content mask-front-content-31">
                <p>
                    M1-directed enzyme prodrug therapy

                </p>
            </div>
            <div class="mask-front-content mask-front-content-32">
                <p>
                    Clinical Application

                </p>
            </div>
        </div>
        <div class="mask mask-3-box">
            <!-- <div class="mask-3 m30"></div> -->
            <div class="mask-3 m31"></div>
            <div class="mask-3 m32"></div>

        </div>
        <div class="rich-content-box">
            <!-- <div class="rich-content rich-content-30">
                <img src="https://2019.igem.org/wiki/images/thumb/2/2d/T--SYSU-Medicine--future_perspectives_1.png/1600px-T--SYSU-Medicine--future_perspectives_1.png"
                    class="img-fp-0">
                <p>
                    &nbsp&nbsp&nbsp&nbspIn our study, we expand the anti-cancer spectrum of oncolytic virus M1 by
                    directed evolution. We
                    plan to explore the characteristics of each mutation site and standardize it as parts, so that
                    we
                    could be combined different mutation according to different purposes. Taking advantages of each
                    mutations, we could obtain the boarder anti-cancer spectrum M1 virus. Further, we can enhance
                    other
                    oncolytic alphavirus through the same method. In addition, through in combination with
                    Actinomycin
                    D, M1 has a great lethality to insensitive cancer cells. M1 armed with nitroreductase could be
                    used
                    to combine with other chemotherapy drugs.
                </p>
            </div> -->
            <div class="rich-content rich-content-31">
                
                <p>
                    &nbsp&nbsp&nbsp&nbspIn combination of M1 with enzyme prodrug and several chemotherapy drugs,
                    such as
                    Actinomycin D,
                    Etoposide, Daunorubicin, etc., our study found that M1-directed enzyme prodrug therapy combined
                    the
                    benefits of oncolytic virus and chemotherapy, increasing the lethality to tumor cells. M1 with
                    enzyme prodrug first delivers the gene to the cancer cell via a viral vector, after the enzyme
                    is
                    expressed, the ability to specifically activate subsequently administered and otherwise inert
                    prodrugs to potent drugs, which allows for a specific therapy with reduced systemic side
                    effects.
                    Furthermore, several studies demonstrated the safety and good targeting of oncolytic virus M1.
                    We
                    also use the riboswitch to increase the regulation of M1. With this characteristic, it can
                    significantly increase the targeting of chemotherapy drugs and reduce its side effects. To
                    maximize
                    the therapeutic efficacy and safety and minimize the side effect of chemotherapy, M1-directed
                    enzyme
                    prodrug therapy has extensive prospect in antitumor therapy
                </p>
                <img src="https://2019.igem.org/wiki/images/thumb/6/60/T--SYSU-Medicine--approach_1.png/1600px-T--SYSU-Medicine--approach_1.png"
                    class="img-fp-1">
            </div>
            <div class="rich-content rich-content-32">
                <img src="https://2019.igem.org/wiki/images/thumb/c/c9/T--SYSU-Medicine--future_perspectives_3.png/1600px-T--SYSU-Medicine--future_perspectives_3.png"
                    class="img-fp-2">
                <p>
                    &nbsp&nbsp&nbsp&nbspVirus-directed enzyme prodrug therapy is one of the major strategy of the
                    targeted delivery of
                    cytotoxic compounds to cancer cells, increasing cytotoxicity of bioreductive agents[1]. The
                    vitro
                    experiment of the prodrug system has demonstrated the effectiveness of the combined therapy.
                    Actinomycin D has been used clinically as a mature chemotherapy for decades and M1 has started
                    phase
                    III clinical trial, with the merit of increasing effective killing of tumor cells and being less
                    damage to the surrounding normal tissues, this combined therapy is possible to be applied to
                    medical
                    and clinical treatment in the future. More researches will be done to promote this therapy.
                </p>
            </div>
        </div>
    </div>
    <div class="reference-box">
        <div class="title-box-new title-4">
            <div class="title-box-mask"></div>
            <div class="title-box-title">
                <h1 class="reference-title">REFERENCE</h1>
            </div>
        </div>
        <div class="reference-content">
            <p>[1] Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. Oncolytic viruses: a new class of immunotherapy
                drugs.
                Nature Reviews Drug Discovery. 2015;14(9), 642-662.
            </p>
            <p>
                [2] Hu J, Cai XF, Yan G. Alphavirus M1 induces apoptosis of malignant glioma cells via
                downregulation
                and nucleolar translocation of p21WAF1/CIP1 protein. Cell Cycle. 2009;8(20):3328–3339.</p>
            <p>
                [3] Fukunaga Y, Kumanomido T, Kamada M. Getah virus as an equine pathogen. Vet Clin North Am Equine
                Pract. 2000;16(3):605–617.
            </p>
            <p>
                [4] Philips, F. S., Schwartz, H. S., Sternberg, S. S., & Tan, C. T. C. THE TOXICITY OF ACTINOMYCIN
                D*.
                Annals of the New York Academy of Sciences, 2006;89(2), 348–360.
            </p>
        </div>
    </div>
    <div class="space" style="height: 30vw;"></div>
</body>
<script>
    $(function () { $(".navigation").css("width", window.innerWidth); });
</script>

</html>